Elevation goes down on Claudin disaster
The honeymoon is over for Claudin18.2, as Elevation drops EO-3021.
Imfinzi puts its flag on the Matterhorn
A hit on EFS will challenge regulators, and points to Merck's design blunder in Keynote-585.
ASCO-GU – another strike against Cabometyx
A triplet did worse than control in first-line kidney cancer.
What future for Lag3 blockade?
Opdualag chalks up another failure, this time in the extension of an approved use.
Cargo can't replicate firi-cel's academic success
Firce-1 is scrapped after showing dismal response rates and patient deaths.
